Literature DB >> 10722481

Intracellular metabolism of beta-L-2',3'-dideoxyadenosine: relevance to its limited antiviral activity.

L Placidi1, E Cretton-Scott, G Gosselin, C Pierra, R F Schinazi, J L Imbach, M H el Kouni, J P Sommadossi.   

Abstract

The intracellular metabolism of the beta-L- enantiomer of 2', 3'-dideoxyadenosine (beta-L-ddA) was investigated in HepG2 cells, human peripheral blood mononuclear cells (PBMC), and primary cultured human hepatocytes in an effort to understand the metabolic basis of its limited activity on the replication of human immunodeficiency virus and hepatitis B virus. Incubation of cells with 10 microM [2',3',8-(3)H]-beta-L-ddA resulted in an increased intracellular concentration of beta-L-ddA with time, demonstrating that these cells were able to transport beta-L-ddA. However, it did not result in the phosphorylation of beta-L-ddA to its pharmacologically active 5'-triphosphate (beta-L-ddATP). Five other intracellular metabolites were detected and identified as beta-L-2', 3'-dideoxyribonolactone, hypoxanthine, inosine, ADP, and ATP, with the last being the predominant metabolite, reaching levels as high as 5.14 +/- 0.95, 8.15 +/- 2.64, and 15.60 +/- 1.74 pmol/10(6) cells at 8, 4, and 2 h in HepG2 cells, PBMC, and hepatocytes, respectively. In addition, a beta-glucuronic derivative of beta-L-ddA was detected in cultured hepatocytes, accounting for 12.5% of the total metabolite pool. Coincubation of hepatocytes in primary culture with beta-L-ddA in the presence of increasing concentrations of 5'-methylthioadenosine resulted in decreased phosphorolysis of beta-L-ddA and formation of associated metabolites. These results indicate that the limited antiviral activity of beta-L-ddA is the result of its inadequate phosphorylation to the nucleotide level due to phosphorolysis and catabolism of beta-L-ddA by methylthioadenosine phosphorylase (EC 2.4.2.28).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722481      PMCID: PMC89782          DOI: 10.1128/AAC.44.4.853-858.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Recent advances in L-nucleosides: chemistry and biology.

Authors:  P Wang; J H Hong; J S Cooperwood; C K Chu
Journal:  Antiviral Res       Date:  1998-12       Impact factor: 5.970

2.  Methionine synthesis from 5'-methylthioadenosine by tumour cells.

Authors:  M J Tisdale
Journal:  Biochem Pharmacol       Date:  1983-10-01       Impact factor: 5.858

3.  Enzymatic properties of the unnatural beta-L-enantiomers of 2',3'-dideoxyadenosine and 2',3'-didehydro-2',3'-dideoxyadenosine.

Authors:  H Pélicano; C Pierra; S Eriksson; G Gosselin; J L Imbach; G Maury
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

4.  Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.

Authors:  M A Johnson; A Fridland
Journal:  Mol Pharmacol       Date:  1989-08       Impact factor: 4.436

5.  A preliminary trial of lamivudine for chronic hepatitis B infection.

Authors:  J L Dienstag; R P Perrillo; E R Schiff; M Bartholomew; C Vicary; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

Review 6.  Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy.

Authors:  C W Porter; J R Sufrin
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

7.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.

Authors:  T S Lin; M Z Luo; M C Liu; Y L Zhu; E Gullen; G E Dutschman; Y C Cheng
Journal:  J Med Chem       Date:  1996-04-26       Impact factor: 7.446

9.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  R F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; M St Clair; J Wilson; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.

Authors:  C K Chu; T Ma; K Shanmuganathan; C Wang; Y Xiang; S B Pai; G Q Yao; J P Sommadossi; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

View more
  1 in total

1.  Antiviral L-nucleosides specific for hepatitis B virus infection.

Authors:  M L Bryant; E G Bridges; L Placidi; A Faraj; A G Loi; C Pierra; D Dukhan; G Gosselin; J L Imbach; B Hernandez; A Juodawlkis; B Tennant; B Korba; P Cote; P Marion; E Cretton-Scott; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.